^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PLB1004

    i
    Other names: PLB1004
    Associations

    News

    Trials
    Company:
    Avistone Biotech
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR Ex20ins Mutation Patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
    P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd. | Trial primary completion date: Apr 2024 --> Oct 2024
    Trial primary completion date • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    PLB1004
    3ms
    Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. (clinicaltrials.gov)
    P2, N=120, Recruiting, Avistone Biotechnology Co., Ltd.
    New P2 trial • Metastases
    |
    Tagrisso (osimertinib) • bozitinib (APL-101) • PLB1004
    4ms
    A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=81, Recruiting, Avistone Biotechnology Co., Ltd. | Active, not recruiting --> Recruiting | Initiation date: Nov 2023 --> Jul 2024
    Enrollment open • Trial initiation date
    |
    EGFR (Epidermal growth factor receptor)
    |
    PLB1004
    8ms
    Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (clinicaltrials.gov)
    P1/2, N=156, Recruiting, Avistone Biotechnology Co., Ltd.
    New P1/2 trial
    |
    bozitinib (APL-101) • PLB1004
    9ms
    Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (clinicaltrials.gov)
    P3, N=327, Not yet recruiting, Avistone Biotechnology Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • PLB1004
    11ms
    A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PLB1004
    1year
    A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=82, Not yet recruiting, Avistone Biotechnology Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PLB1004
    1year
    Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
    P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd.
    New P2 trial • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    PLB1004
    over1year
    Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1, N=91, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: May 2022 --> Apr 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    PLB1004